Search PubMed⌕ Search

Biomedical subjects

C Gisselbrecht

Publications and source records attributed to C Gisselbrecht.

203 records · Page 12Linked to original sources
PubMedDate not supplied

[Pharmacokinetics use in anti-cancer therapy (author's transl)].

Dynamic studies of anti-neoplasic agents provide a mathematical expression of various biological steps. High specific technics of dosage make possible the measurements of the drugs and their metabolites. Pharmacokinetics provides a new approach to three fundamental aspects in oncology: drug toxicity, relationship between drug schedule and response in each individual, drug resistance to anticancer drugs. Rational therapeutic approaches are made possible, as it was shown by the use of high dose of methotrexate.

Animals↗
PubMedDate not supplied

[Hodgkin's disease. Residual histologically stable masses after chemotherapy].

In 4 patients with Hodgkin's disease treated with chemotherapy persistent residual masses, remarkable by their initial volume in 3 cases, were surgically removed. Histological examination showed that the masses were histologically stable and non-evolutive. The incidence of residual masses is discussed with a review of the literature. These masses, which should not be confused with therapeutic failures, constitute a striking example of the special place occupied by surgery in certain forms of Hodgkin's disease.

Adult↗
PubMedDate not supplied

[Current advances in cancer immunotherapy (author's transl)].

Immunotherapy is still considered as an important therapeutic method in oncology. Experimental basis do exist which support the individualization of several distinct conditions of immunomodulation, some of them being associated with a therapeutic benefit. Numerous immunomodulation molecules or derivatives are now available for clinical investigations. However, effects of immunomodulators on the immune systems which depend on several unknown factors are actually not always fairly correlated with antitumoral effects. Clinical trials are therefore needed in order to demonstrate that immunotherapy remains a valuable antitumoral treatment. The authors review here the available data obtained from recent clinical studies in man. They attempt to establish the limits of immunotherapy as well as its future possibilities.

BCG Vaccine↗
PubMedDate not supplied

[The role of autografts in severe or metastatic breast cancers].

Intensive treatment of poor prognosis breast cancer has included bone marrow autografts. A multicentric study was conducted from 1988 to 1992, including 105 patients with a minimal follow-up of 2 years after the autograft. Inclusion criteria were: age < 55 years, measurable metastasis, inflammatory breast cancer, breast cancer with major lymph node invasion (> 8 N+). Chemotherapy (6 to 8 cycles) was used initially. In responders, bone marrow was harvested and frozen. Medullary invasion had to be absent for bone marrow harvesting. Management then included cyclophosphamide: 60 mg/kg, D-7, D-6; mitoxantrone: 12 mg/m2, D-9 to D-5; alkeran: 140 mg/m2, D-2 followed D0 for bone marrow autograft. For the 105 patients, mean age was 40 years; inflammatory breast cancer: 33 patients; > or = 8 N+: 11 patients; metastasis: 61 patients. For the cases with metastasis, the main sites were: liver: 24 patients, lung: 14 patients, bone: 22 patients, central nervous system: 4 patients. Nineteen patients had at least two metastasis localizations. Responders alone were included although 7 patients had been stabilized before the autograft. For the metastatic forms, median survival was 41 +/- 9 months from the onset to diagnosis of metastasis, with 8 patients surviving over 5 years. Median survival without progression was 12 months with a 4-year probability of 17%. For inflammatory breast cancers, the probability of survival was 50% and survival without progression was 42%. For patients with lymph node invasion > or = 8 N+, it was 72%.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗